Please login to the form below

Not currently logged in
Email:
Password:

drug licensing

This page shows the latest drug licensing news and features for those working in and with pharma, biotech and healthcare.

Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum

Plasticell and London’s gene therapy pioneers to tackle manufacturing conundrum

This is an excellent opportunity to improve the manufacturing technology as we move towards drug licensing”commented Professor Adrian Thrasher, Fellow at the UCL Great Ormond Street Institute of Child Health.

Latest news

  • Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug Novo Nordisk pays $400m for EpiDestiny’s sickle cell drug

    Novo Nordisk has bolstered its biopharma unit with a global licensing deal for a small-molecule drug for genetic blood disorders sickle cell disease and beta thalassaemia. ... II/III trials of the drug in oncology before the end of the year.

  • Onyx Health wins two new accounts

    The marketing communications agency will strengthen Newcells’position in the drug discovery outsourcing market. ... Dr Mike Nicholds, chief executive officer at Newcells Biotech, said: “A new drug can take on average over ten years from initial

  • European Commission approves Dompé’s orphan drug European Commission approves Dompé’s orphan drug

    European Commission approves Dompé’ s orphan drug. Oxervate will treat patients with neurotrophic keratitis. ... Aringhieri added: “Oxervate is our first biotech drug and its licensing is due to the hard work of a skilled and passionate team that

  • Marathon pauses Emflaza launch amid pricing furore Marathon pauses Emflaza launch amid pricing furore

    Marathon pauses Emflaza launch amid pricing furore. US Senator Bernie Sanders calls Duchenne muscular dystrophy drug’ s pricing “ unconscionable”. ... They want information on the cost of trials as well as licensing rights to the drug, the

  • AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn

    AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn. Will receive $250m upfront with a further $1.27bn if drug reaches market in two indications. ... AstraZeneca's streamlining exercise continues this week with the licensing of mid-stage

More from news
Approximately 1 fully matching, plus 60 partially matching documents found.

Latest Intelligence

  • Charting a course for expansion Charting a course for expansion

    The drug treats the hormonal disorder acromegaly and neuroendocrine tumours (NETs), a rare form of cancer. ... Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing

  • Pharma deals during January 2013 Pharma deals during January 2013

    Out licensing WW rights to RN 307 antibody (binds to calcitonin related peptide) phase II ready. ... 18-MC (18-methoxycoronaridine) as a treatment for drug addiction, obesity and compulsive behaviour.

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    However, Sanofi has since discontinued its development. The company announced in May 2011 that the drug is available for licensing. ... The drug is also in phase III development for the acute treatment of VTE.

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Ipsen bolsters leadership team Ipsen bolsters leadership team

    Prior to this, she has served as senior vice president, head of global business development at Teva Pharmaceuticals, where she led and executed multiple business development transactions ranging from licensing to ... acquisition of drug candidates,

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Drivers of 2014′s Soaring Drug Approvals

    Drivers of 2014′ s Soaring Drug Approvals. The FDA EMA approved a chart-topping number of new drugs in 2014. ... To read our White Paper please click on the following link: . . Drivers of 2014′ s Soaring Drug Approvals.

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics